文献速递介入腹部USDSA

肝细胞癌首次射频消融失败后:重复射频消融与经动脉化疗栓塞的比较

Initial radiofrequency ablation failure for hepatocellular carcinoma: repeated radiofrequency ablation versus transarterial chemoembolisation.
PubMed 文献 · Clin Radiol · 2017-08-30

回顾性研究纳入713例以射频消融作为一线治疗的单个肝细胞癌患者中58例首次消融后出现局部肿瘤进展者,分别接受重复射频消融(33例)或经动脉化疗栓塞(25例)。两组5年无复发生存率(17% vs 10.7%)和总生存率(72.7% vs 51.9%)均无显著差异,多因素分析显示治疗方式与预后无关。作者认为当重复射频消融不可行时,经动脉化疗栓塞是有效的替代治疗。

要点

  • 首次射频消融后局部肿瘤进展患者中,重复射频消融与经动脉化疗栓塞的5年无复发生存和总生存无显著差异。
  • 经动脉化疗栓塞作为重复射频消融不可行时的替代选择,疗效与重复射频消融相当。
  • 两组基线特征仅膈下肿瘤比例存在差异(p=0.031),可能影响治疗选择。

核心结论

  • 对于肝细胞癌首次射频消融后出现局部肿瘤进展的患者,当重复射频消融不可行时,经动脉化疗栓塞是有效的治疗选择,其疗效与重复射频消融相当。

研究设计与样本

  • 回顾性研究,纳入2006年7月至2012年2月间713例以射频消融作为一线治疗的单个肝细胞癌患者中58例首次消融后出现局部肿瘤进展者,其中重复射频消融组33例、经动脉化疗栓塞组25例;经动脉化疗栓塞在计划超声评估重复射频消融不可行时作为替代方案;采用Kaplan-Meier法估计无复发生存率和总生存率,Cox比例风险模型评估预后因素。

诊断标准与关键数值

  • 重复射频消融组与经动脉化疗栓塞组的5年无复发生存率分别为17%和10.7%,差异无统计学意义(p>0.05)。
  • 重复射频消融组与经动脉化疗栓塞组的5年总生存率分别为72.7%和51.9%,差异无统计学意义(p>0.05)。
  • 多因素分析显示治疗方式与无复发生存或总生存无关。

临床应用与阅片要点

  • 当计划超声评估重复射频消融不可行时,可考虑经动脉化疗栓塞作为局部肿瘤进展的替代治疗。
  • 两组基线特征除膈下肿瘤比例外无显著差异,膈下肿瘤比例差异(p=0.031)可能影响治疗方式选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To compare the long-term therapeutic outcomes of repeated radiofrequency ablation (RFA) with that of transarterial chemoembolisation (TACE) in patients with local tumour progression (LTP) after initial RFA treatment for hepatocellular carcinoma (HCC).

MATERIALS AND METHODS: This retrospective study was approved by the institutional review board and the requirement for informed consent was waived. Between July 2006 and February 2012, 713 patients underwent RFA for single HCC as a first-line treatment. Fifty-eight patients who showed LTP as initial tumour recurrence post-RFA treatment were included. Patients were treated with either repeated RFA (n=33) or TACE (n=25). TACE was performed as an alternative therapeutic option when repeated RFA was not feasible based on the planning ultrasonography. Recurrence-free and overall survival rates were estimated using the Kaplan-Meier method. Prognostic factors for outcomes were evaluated using the Cox proportional hazards model.

RESULTS: Both groups did not show significant differences in terms of baseline characteristics, with the exception being the proportion of subphrenic tumours (p=0.031). The RFA and TACE groups did not differ significantly in their 5-year recurrence-free and overall survival rates (17% versus 10.7% and 72.7% versus 51.9%, respectively, with all p-values >0.05). In addition, multivariate analyses revealed that type of treatment was not associated with recurrence-free or overall survival in patients with post-RFA LTP.

CONCLUSION: TACE is an effective treatment, comparable to repeated RFA, in patients with LTP after initial RFA when repeated RFA is not feasible.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Kim SS, Kang TW, Kim M, et al. Initial radiofrequency ablation failure for hepatocellular carcinoma: repeated radiofrequency ablation versus transarterial chemoembolisation. Clin Radiol. 2017. PMID: 28859852. doi:10.1016/j.crad.2017.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。